XERS Q3 2021 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$982M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+16.8% YoY

Gross Profit

$8M70.8% margin

Operating Income

-$24M-220.7% margin

Net Income

-$26M-235.7% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+23.9%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$131M

Total Liabilities

$134M

Stockholders' Equity

-$2M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$9M	+16.8%
Gross Profit	$8M	$7M	+18.1%
Operating Income	-$24M	-$14M	-77.2%
Net Income	-$26M	-$16M	-62.6%